157-03-9
157-03-9
Chemical Structure
6-Diazo-5-oxo-L-nor-Leucine
Synonym(s): L-6-Diazo-5-oxonorleucine; DON
- CAS No.: 157-03-9
- Formula:C6H9N3O3
- Molecular Weight:171.15
IUPAC Name: (S)-2-amino-6-diazo-5-oxohexanoic acid
InChIKey: YCWQAMGASJSUIP-YFKPBYRVSA-N
SMILES: N[C@@H](CCC(C=[N+]=[N-])=O)C(O)=O
Biological Activity: 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
6-Diazo-5-oxo-L-nor-Leucine | 99.98% | 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
6-Diazo-5-oxo-L-nor-Leucine (Standard) | ≥98% | 6-Diazo-5-oxo-L-nor-Leucine (Standard) is the analytical standard of 6-Diazo-5-oxo-L-nor-Leucine. This product is intended for research and analytical applications. 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid-13C5,15N | D-Glutamic acid-13C5,15N ((R)-Glutamic acid-13C5,15N) is 13C and 15N labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Glutamic acid-13C5 | D-Glutamic acid-13C5 ((R)-Glutamic acid-13C5) is 13C labeled D-Glutamic acid. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Duazomycin | Duazomycin A is a glutamine antagonist. Duazomycin A can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) (HY-13677) in experimental allergic encephalomyelitis (EAE) without increasing toxicity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C | 99.9% | L-Glutamic acid-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C2 | 99.7% | L-Glutamic acid-13C2 is the 13C labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-15N | 98.0% | L-Glutamic acid-15N is the 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C5,15N | 99.9% | L-Glutamic acid-13C5,15N is the 13C- and 15N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Glutamic acid-13C5 | 99.81% | L-Glutamic acid-13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Diazo-4-oxonorvaline | 5-Diazo-4-oxonorvaline is a type of asparagine analogue, belonging to diazo compounds. 5-Diazo-4-oxonorvaline can specifically target the active site of glycosyl asparaginase (Ki = 80 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
6-Diazo-5-oxo-D-norleucine | 6-Diazo-5-oxo-D-norleucine, a D-Glutamine (HY-100587) analog, is a γ-glutamyl transferase inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Willis RC, et al. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast. J Cell Physiol. 1977 Dec;93(3):375-82. [Content Brief]
- [2]. Sharma NS, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2019 Oct 15. [Content Brief]
- [3]. DeWald H A, et al. 6-diazo-5-oxo-l-norleucine, a new tumor-inhibitory substance. 1a preparation of l-, d-and dl-forms1b. Journal of the American Chemical Society, 1958, 80(15): 3941-3945.
